Almac Announces Release of Enhanced 3PL Customer Billing Application
News Nov 19, 2013
Almac has announced the release of an enhanced 3rd Party Logistics (3PL) Customer Billing Application.
In response to growing client demand for fully integrated end to end support of EU product launches, from import testing, country specific packaging, QP release, online ordering, direct to pharmacy distribution and financial services, Almac have enhanced their customer billing software to facilitate a seamless invoicing process on behalf of 3PL clients.
3PL orders, received directly from hospitals / clinics / pharmacies, for niche/ orphan drug products, will now be processed, dispatched, and automatically invoiced on the client’s behalf.
The process will be completed by reconciliation of payments to the client’s EU account, as well as debtor follow up.
David Downey, VP Commercial Operations of Almac explains “With our client partners, we have successfully launched many high-value, orphan drug / niche products into the European market. With this enhancement to our customer billing application, we can alleviate the client’s administrative burden, by essentially becoming an extension of their supply chain team and assist in managing cash receipts and debtor follow up. Particularly for US based clients with no EU operational footprint, this end to end service provides a compelling business case to partner with an experienced EU solutions provider.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE